U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Rearrangement of 2p23

MedGen UID:
308126
•Concept ID:
C1514750
•
Cell or Molecular Dysfunction

Recent clinical studies

Etiology

A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM, Parker JV, Lymperopoulos A, Konda V
J Oncol Pharm Pract 2019 Jul;25(5):1226-1230. Epub 2018 Jun 20 doi: 10.1177/1078155218781944. PMID: 29925295
High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC
J Thorac Oncol 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. PMID: 24722154
Assessment of t(2;5)(p23;q35) translocation and variants in pediatric ALK+ anaplastic large cell lymphoma.
Liang X, Meech SJ, Odom LF, Bitter MA, Ryder JW, Hunger SP, Lovell MA, Meltesen L, Wei Q, Williams SA, Hutchinson RN, McGavran L
Am J Clin Pathol 2004 Apr;121(4):496-506. doi: 10.1309/TLE8-FN6E-YF0N-JGP7. PMID: 15080301
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA
Mod Pathol 2001 Jun;14(6):569-76. doi: 10.1038/modpathol.3880352. PMID: 11406658
Involvement of 2p23 in pulmonary inflammatory pseudotumors.
Yousem SA, Shaw H, Cieply K
Hum Pathol 2001 Apr;32(4):428-33. doi: 10.1053/hupa.2001.23523. PMID: 11331960

Diagnosis

ALK-rearranged renal cell carcinoma (ALK-RCC): Evaluation of histomorphological and immunohistochemical features by analysis of 276 renal cell carcinoma cases in Turkey.
Doğan K, Onder E
Pathol Res Pract 2024 Jan;253:154951. Epub 2023 Nov 20 doi: 10.1016/j.prp.2023.154951. PMID: 38039739
ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y, Liu N, Guo W, Pu X, Guo H, Gan W, Li D
Pathol Res Pract 2020 Dec;216(12):153286. Epub 2020 Nov 9 doi: 10.1016/j.prp.2020.153286. PMID: 33197836
Collision Tumor Composed of an Inflammatory Myofibroblastic Tumor and Adenocarcinoma of the Colon: a Rare Entity.
Cornacchia C, Rutigliani M, Belli F, Romano N, Serventi A, Fiocca R, Filauro M
J Gastrointestin Liver Dis 2020 Sep 9;29(3):461-463. doi: 10.15403/jgld-782. PMID: 32919426
High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC
J Thorac Oncol 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. PMID: 24722154
Inflammatory myofibroblastic tumors of the head and neck: evaluation of clinicopathologic and prognostic features.
Devaney KO, Lafeir DJ, Triantafyllou A, Mendenhall WM, Woolgar JA, Rinaldo A, Ferlito A
Eur Arch Otorhinolaryngol 2012 Dec;269(12):2461-5. Epub 2012 May 16 doi: 10.1007/s00405-012-2026-3. PMID: 22588194

Therapy

A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM, Parker JV, Lymperopoulos A, Konda V
J Oncol Pharm Pract 2019 Jul;25(5):1226-1230. Epub 2018 Jun 20 doi: 10.1177/1078155218781944. PMID: 29925295
High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC
J Thorac Oncol 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. PMID: 24722154
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI
N Engl J Med 2010 Oct 28;363(18):1727-33. doi: 10.1056/NEJMoa1007056. PMID: 20979472Free PMC Article
Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia.
Mathew S, Head D, Rubnitz JE, Raimondi SC
Genes Chromosomes Cancer 2000 Jun;28(2):227-32. PMID: 10825008
Chromosome rearrangements in fumigant appliers: possible relationship to non-Hodgkin's lymphoma risk.
Garry VF, Danzl TJ, Tarone R, Griffith J, Cervenka J, Krueger L, Whorton EB Jr, Nelson RL
Cancer Epidemiol Biomarkers Prev 1992 May-Jun;1(4):287-91. PMID: 1303128

Prognosis

ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y, Liu N, Guo W, Pu X, Guo H, Gan W, Li D
Pathol Res Pract 2020 Dec;216(12):153286. Epub 2020 Nov 9 doi: 10.1016/j.prp.2020.153286. PMID: 33197836
Collision Tumor Composed of an Inflammatory Myofibroblastic Tumor and Adenocarcinoma of the Colon: a Rare Entity.
Cornacchia C, Rutigliani M, Belli F, Romano N, Serventi A, Fiocca R, Filauro M
J Gastrointestin Liver Dis 2020 Sep 9;29(3):461-463. doi: 10.15403/jgld-782. PMID: 32919426
RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
Lim JH, Jang S, Park CJ, Cho YU, Lee JH, Lee KH, Lee JO, Shin JY, Kim JI, Huh J, Seo EJ
Cancer Genet 2014 Jan-Feb;207(1-2):40-5. Epub 2014 Jan 21 doi: 10.1016/j.cancergen.2013.12.003. PMID: 24613277
Inflammatory myofibroblastic tumors of the head and neck: evaluation of clinicopathologic and prognostic features.
Devaney KO, Lafeir DJ, Triantafyllou A, Mendenhall WM, Woolgar JA, Rinaldo A, Ferlito A
Eur Arch Otorhinolaryngol 2012 Dec;269(12):2461-5. Epub 2012 May 16 doi: 10.1007/s00405-012-2026-3. PMID: 22588194
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA
Mod Pathol 2001 Jun;14(6):569-76. doi: 10.1038/modpathol.3880352. PMID: 11406658

Clinical prediction guides

ALK rearrangement in TFE3-positive renal cell carcinoma: Alternative diagnostic option to exclude Xp11.2 translocation carcinoma.
Zhu Y, Liu N, Guo W, Pu X, Guo H, Gan W, Li D
Pathol Res Pract 2020 Dec;216(12):153286. Epub 2020 Nov 9 doi: 10.1016/j.prp.2020.153286. PMID: 33197836
Genomic characterization of ependymomas reveals 6q loss as the most common aberration.
Olsen TK, Gorunova L, Meling TR, Micci F, Scheie D, Due-Tønnessen B, Heim S, Brandal P
Oncol Rep 2014 Aug;32(2):483-90. Epub 2014 Jun 16 doi: 10.3892/or.2014.3271. PMID: 24939246Free PMC Article
High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y, Minca EC, Lanigan C, Liu A, Zhang W, Yin L, Pennell NA, Farver C, Tubbs R, Ma PC
J Thorac Oncol 2014 May;9(5):646-53. doi: 10.1097/JTO.0000000000000145. PMID: 24722154
Recurrent inverted duplication of 2p with terminal deletion in a patient with the classical phenotype of trisomy 2p23-pter.
Gruchy N, Jacquemont ML, Lyonnet S, Labrune P, El Kamel I, Siffroi JP, Portnoï MF
Am J Med Genet A 2007 Oct 15;143A(20):2417-22. doi: 10.1002/ajmg.a.31931. PMID: 17853488
ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor.
Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA
Mod Pathol 2001 Jun;14(6):569-76. doi: 10.1038/modpathol.3880352. PMID: 11406658

Supplemental Content

Table of contents

    Practice guidelines

    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...